key: cord-0782287-xsj63027
authors: Amer, Rania M.; Samir, Mohamed; Gaber, Osama A.; EL-Deeb, Nahawand A.; Abdelmoaty, Ahmed A.; Ahmed, Alshymaa A.; Samy, Walaa; Atta, Amal H.; Walaa, Mohammad; Anis, Reham H.
title: Diagnostic performance of rapid antigen test for COVID-19 and the effect of viral load, sampling time, subject’s clinical and laboratory parameters on test accuracy
date: 2021-06-11
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.06.002
sha: ac3c8a2542514006ddbb88c0c3a783ddde428e48
doc_id: 782287
cord_uid: xsj63027

Background Egypt was among the first 10 countries in Africa that experienced COVID-19 cases. The sudden surge in the number of cases is overwhelming the capacity of the national healthcare system, particularly in developing countries. Central to the containment of the ongoing pandemic is the availability of rapid and accurate diagnostic tests that could pinpoint patients at early disease stages. In the current study, we aimed to (1) Evaluate the diagnostic performance of the rapid antigen test (RAT) “Standard™ Q COVID-19 Ag” against reverse transcriptase quantitative real-time PCR (RT-qPCR) in eighty-three swabs collected from COVID-19 suspected individuals showing various demographic features, clinical and radiological findings. (2) Test whether measuring laboratory parameters in participant’s blood would enhance the predictive accuracy of RAT. (3) Identify the most important features that determine the results of both RAT and RT-qPCR. Methods Diagnostic measurements (e.g. sensitivity, specificity, etc.) and receiver operating characteristic curve was used to assess the clinical performance of “Standard™ Q COVID-19 Ag”. We used the support vector machine (SVM) model to investigate whether measuring laboratory indices would enhance the accuracy of RAT. Moreover, a random forest classification model was used to determine the most important determinants of the results of RAT and RT-qPCR for COVID-19 diagnosis. Results The sensitivity, specificity, and accuracy of RAT were 78.2, 64.2, and 75.9%, respectively. Samples with high viral load and those that were collected within one-week post-symptoms showed the highest sensitivity and accuracy. The SVM modeling showed that measuring laboratory indices did not enhance the predictive accuracy of RAT. Conclusion “Standard™ Q COVID-19 Ag” should not be used alone for COVID-19 diagnosis due to its low diagnostic performance relative to the RT-qPCR. RAT is best used at the early disease stage and in patients with high viral load.

Infection with Coronavirus (CoV) diseases , which is caused by novel severe acute respiratory syndrome CoV-2 (SARS-CoV-2), was firstly reported in Wuhan city, Hubei province, China in December 2019 [1] . On 11 March 2020, the World Health Organization (WHO) declared COVID-19 as a pandemic of global concern [2] . There has been a tremendous increase in the number of confirmed cases as well as death records worldwide. As of 24 March 2021, ~ 123 million COVID-19 cases were confirmed worldwide and more than two million deaths were reported [3] . Egypt was among the first 10 countries in Africa that experienced COVID-19 cases [4] . By this date, Egypt has reported 197 confirmed cases with 5.9% of them died of the pandemic [3] . The sudden and unprecedented surge in the number of reported cases is overwhelming the capacity of the national healthcare system, particularly in developing countries [5] . Central to the containment of the ongoing pandemic is the availability of rapid and accurate diagnostic tests that could pinpoint patients at early disease stages before further spread occurs.

Reverse transcriptase quantitative real-time PCR (RT-qPCR) assay has been the gold standard for diagnosing COVID-19 in many health sectors and laboratories [6] [7] [8] .

However, this assay is often done in large centralized hospitals or laboratories away from the access of local inhabitants; it requires long time-to-results, skilled staff, and specialized instruments and is of high cost [9] . This is particularly the case in many developing countries, including Egypt [10] . In Egypt, the RT-qPCR diagnosis is mostly done in Cairo, the capital, or in capitals of governorates leading to an overall turn-aroundtime of ~ 24 hours at best between shipping the samples and obtaining the results [11] .

Indeed, suspected individuals often go first to the local clinics for an emergency where RT-qPCR might not be available. The RT-qPCR may thus not be able to cope with the testing or screening needs in the low and middle-income countries due to limited J o u r n a l P r e -p r o o f infrastructure, low fund, and limited human resources [12] . To fill in this gap and to improve this situation, rapid antigen tests (RATs) are being developed and are in use as point-ofcare diagnostic tools [13] . They offer the advantage of being quick and can be done simply without the need for special equipment [14] [15] [16] . Determining the diagnostic performance of commercialized RAT is crucial because this gives an indication of their reliability and clinical utility during the time of the pandemic.

With the availability of both RT-qPCR and RAT for diagnosis of COVID-19 suspected individuals, it is worth comparing their diagnostic performance to unravel advantages and disadvantages of using both tests, and thus determine the preference of using any of them over the other in various pandemic scenarios. This is done taken into account the fundamental differences between both assays in methodology and application. There have been many RAT available for diagnosis of COVID-19 (reviewed in [9, 12] ), yet their clinical applicability is questionable because their accuracy has shown to be low as compared to RT-qPCR, their diagnostic performance is highly variable, even when the same assay was applied in two different population with different ethnicity background [15, 17] and their accuracy is host-and virus-dependent [6, 17] 

Eighty-three nasopharyngeal (NP) and oropharyngeal swabs (OP) were obtained by trained health staff at the isolation units. Based on the recommendation from the Center for Disease Control and Prevention (CDC) [21] and to maximize sensitivity and to limit the use of test resources, the two NP and OP swabs were taken from one participant were admixed in a 3-ml tube containing viral transport medium (VTM, Ismailia free zone, Egypt.

Ref: 1/V T01.001.0001) and stored at -80 °C until further analyses. 

The RT-qPCR-characterized samples were tested with the RAT Standard ™ Q COVID-19 Ag test (SD Biosensor, Inc., Republic of Korea). The standard ™ Q COVID-19 Ag test is an immunoassay that detects SARS-CoV-2 nucleocapsid protein by lateral flow technique. The test device consists of a membrane with control and test lines that are precoated with mouse monoclonal anti-SARS-CoV-2 antibody and anti-chicken IgG antibody, respectively. The anti-SARS-CoV-2 antibody is conjugated with color particles and is used J o u r n a l P r e -p r o o f as detectors for SARS-CoV-2 antigen. A colored test line would be visible, with various intensities, if SARS-CoV-2 nucleocapsid protein were present in the specimen. The test procedure was all done under BSL-2 following the manufacturer's instruction. Briefly, the VTM, containing the NP and OP fluids, was first vortexed for 20 seconds and only 100 μl thereof was placed into the sample port of the cassette and incubated at room temperature for 15-30 minutes until reading the results in a blinded approach (i.e. without knowing the RT-qPCR results of the samples).

Continuous variables (e.g. age) were expressed as median ± SD and were compared using the Mann Whitney U test. Categorical variables were expressed as numbers and percentages and were compared using ꭓ2 or Fisher's exact test. Correlation and agreement between RAT and RT-qPCR results were calculated using Pearson's correlation (r) and Cohn's kappa (κ), respectively [22] . Measurements of diagnostic performance of RAT (sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and likelihood ratio) for the whole subjects and subject's subgroups were calculated on contingency tables containing the numbers of each outcome. The confidence intervals (CI) were calculated using the Wilson-Brown method [23] .

Participant's categories based on Ct values were defined following a previous report [15] .

A receiver operating characteristic curve (ROC) was generated to provide another assessment for the diagnostic power of the RAT. These analyses were done using GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, California USA, (www.graphpad.com). To investigate whether combining measurements of blood parameters would by any means enhance the predictive accuracy of the RAT and thus raises its clinical utility, a support vector machine (SVM) model with Monte-Carlo crossvalidation was applied as described previously [24] and the performance of top-ranked combination (best model) was evaluated for sensitivity, specificity, and accuracy using class probability analysis. This analysis was done on data from 68 subjects (the other 15 subjects had no data on any of the laboratory parameters). Random forest classification was utilized to reveal the demographic and clinical parameters that are most important in J o u r n a l P r e -p r o o f determining individuals with positive and negative results for both RAT and RT-qPCR. In both SVM and random forest models, the singular value decomposition method was used to impute the missing values [25] . These analyses were done using Metaboanalyst online server [26] .

The demographic and baseline clinical characteristics of the participants are summarized in Table 1 As shown in Table 2 and Fig. 1 Table S2 . The ROC analysis yielded an AUC value of 0.7 ±0.08 (Ci = 0.0.5-0.8, P-value = 0.02) (Fig. 2 a) .

Effect of subjects' demographic, clinical criteria, and sampling time on the results of the RAT Table 3 and S2 show the diagnostic performance of the RAT in various subject's subgroups. Although RAT results did not differ significantly between male and female subjects, it was slightly more sensitive and more accurate in female (sensitivity = 78.5% and accuracy = 79.4%) than in male (sensitivity = 76.1% and accuracy = 71.4%) participants and its specificity in female was almost twice (83.3%) than in male subjects (42.8%). High sensitivity and accuracy were evident when swabs were collected 0-7 days post-symptoms (n of subjects = 38) followed in order by the case when swabs were taken at 8-16 (n of subjects = 27) and >16 days post-symptoms (n of subjects = 4). There were no significant differences in the RAT results between symptomatic, radiology-positive subjects and asymptomatic, radiology-negative subjects, respectively. However, RAT was more sensitive and accurate in symptomatic subjects relative to the asymptomatic ones. showed symptoms 5-days after the sampling. RAT showed higher sensitivity and accuracy in subjects with no radiological findings than those with radiological findings. No radiological findings were evident in seven participants, 6 of whom were positive by both RAT and RT-qPCR.

Considering the intermediate diagnostic power (AUC = 0.7) (Fig. 2 a) and the low diagnostic performance of the RAT (Table 2 and 3), we investigated whether combining laboratory indices measured in blood with the results RAT would enhance the true identification of COVID-19 patients by RAT. First, the SVM model revealed that HB, urea, RAT, and S. ferritin were the top-4 parameters most frequently selected during the model building and cross-validation followed by the other features (Fig. 2 b) . The various combination between these parameters (i.e. those listed in ascending order in Fig. 2 b) yielded various accuracies in predicting true COVID-19 cases. The highest prediction accuracy (59.3%) was obtained when combining RAT with both HB and urea (top 2features in Fig. 2 b) . Coupling RAT with HB, urea, S. ferritin, and CRP (top 5-ranked features) yielded slightly lower prediction accuracy (58%) than the one produced by the 3-feature model. Combining all features together revealed low prediction accuracy of 48%. Subsequent evaluation of the "top 3-feature" model by predictive class probability analyses (Fig. 2 d) 

As shown in Fig. S1 , It was found that the sampling time post-symptom onset was the most significant parameter that determines the results in both assays. The order of importance of other parameters differed between the RT-qPCR and the RAT. Dyspnea and radiological findings were the top two parameters for the RT-qPCR results, whereas the subject's age and chest pain were the most important features of the RAT.

In this study, we aimed to evaluate the diagnostic performance of Standard ™Q COVID-19 Ag test, a recently commercialized RAT in Egypt, and to investigate the patient' features that could influence test performance. Determining the diagnostic performance of commercialized RAT is crucial because this gives an indication of their reliability and clinical utility during the time of the pandemic. Our data suggest that RAT has low performance as compared to the RT-qPCR. Combining laboratory parameters with RAT did not enhance RAT predictive accuracy. To the best of our knowledge, this study deems the first one in Egypt that provides a detailed evaluation of the diagnostic performance of a RAT against RT-qPCR on Egyptian subjects.

Indeed, RT-qPCR and RAT differ in terms of protocols, core idea, targets and application.

As both of the test were in use during COVID-19 pandemic, comparing their ability to identify truly infected individuals have become an important and logical point of research [6, 17] .

Given that the ideal RAT should have a sensitivity > 95% and a specificity of 100% [15] , The Standard ™Q COVID-19 Ag studied here showed less than optimal performance. does not necessarily mean that he/she is infectious. Our data indicated the majority of the 15 false-negative patients by RAT had a low viral load, although being symptomatic (Table S1 ). Since we did not isolate live viruses from those patients, their infectiousness remains unknown and the presence of symptoms does not imply that the person is infectious as shown previously for COVID-19 patients with low viral load [27] . Symptoms in those "low or no viral load" groups could be attributed to virus-induced end-organ damage, as shown in their radiological findings, rather than the presence of replicating virus. On the other side, the lack of specificity could lead to extra cost due to the wrong decision of isolation or advising needless therapy. At the time of writing this paper, we are analyzing clinical data from a big Egyptian cohort, which might solidify some of these conclusions. The current RAT showed higher sensitivity and lower specificity when it was applied in 262 Ugandan subjects [15] . RAT had higher sensitivity (98.3%) and higher specificity (98.7%) than our results when applied on 454 subjects from Thailand [17] . This indicates that test results might be race/ethnicity-dependent. Our data add to the already known diversity in RATs results. The sensitivity of the current RAT was higher than that obtained by BIOCREDIT COVID-19 Ag test (43.1%) applied on nasal swabs in Egypt [18] .

In two independent studies, Ag Respi-Strip (Coris Bioconcept, Gembloux, Belgium) exhibited specificity of 100% and sensitivity ranged from 30-50% [14, 16] . Fluorescence RAT done on 239 participants in China showed low sensitivity of 68% and maximum specificity (100%) [28] . The fluorescence immunochromatographic assay produced 93.9% sensitivity and 100% specificity when used on 127 subjects from Chile [29] . The differences in test performance could be due to variabilities in the participant's clinical features, sample type and processing, PCR protocol, and viral load in samples. When evaluating any RAT performance, it is worth noting that misdiagnosis of COVID-19 patients could be due to the presence of many virus variants and thus difference between the virus strain contained in the sample and the virus strain against which the antibodies coated in the RAT were raised. This is highlighted knowing that Standard ™ Q COVID-19

Ag was designed to detect the original WUHAN-01 strain and that mutation rate is high in the antibody-target SARS-CoV-2 N protein [30] . It is therefore recommended to continuously evaluate and update the validity of this and other RAT when applied in J o u r n a l P r e -p r o o f different communities that might experience other SARS-CoV-2 strains especially with the beginning of the second wave.

Our data showed that the Standard ™ Q COVID-19 Ag was more sensitive and more accurate in patients with a high viral load than those with low viral load. Similar results were shown for the same RAT in Uganda [15] and for other qualitative [14, 29, 31] and quantitative [32] RATs. In parallel, RAT showed the highest sensitivity and accuracy in the samples collected during the first-week post-symptoms, and sampling time was the top important feature that determines the results of both RT-qPCR and RAT as revealed by our random forest classification (Fig. S1) . These findings support previous studies that reported a 14% decrease in sensitivity of fluorescence immunochromatographic assay when performed on samples collected between 8-12 days post-symptoms relative to earlier samples [29] . It is already known that SARS-CoV-2 load in upper respiratory tract samples often peaks few days after symptom onset [33, 34] . This complements our results Many studies exist that analyzed the performance of RAT, yet limited studies correlate patient's clinical and radiological features to the RAT performance. Our observation that Standard™ Q COVID-19 Ag test has higher sensitivity and accuracy in symptomatic than asymptomatic subjects is in line with the previous study done on 3410 Italian patients using the same assay, where the RAT's sensitivity declined from 89.9% in symptomatic subjects to 50% in the asymptomatic ones. Our analyses indicated that the Standard™ Q COVID-19 Ag test was able to detect, albeit with a very faint line, RT-qPCR-negative subjects who were asymptomatic and had no radiological alteration. This highlights the importance of subjecting asymptomatic suspected individuals to the test and that RAT might be sensitive enough to truly detect asymptomatic carriers, who likely account for a significant portion of disease transmission events among humans [35] . Additional analyses are needed to better evaluate this RAT in asymptomatic subjects, since our J o u r n a l P r e -p r o o f study included low number of this category (n = 5). Our data indicate the low clinical value of radiological analyses in determining COVID-19 patients relative to RT-qPCR or even the RAT since all participants who had no radiological alteration proved positive by RT-qPCR (4 of them have high Ct value > 25) and five of them were also positive by RAT.

Obviously, additional analyses are needed to generalize these observations. From a diagnosis point of view, particularly in the absence of RT-qPCR in local sites, it might be useful to combine RAT results with laboratory measurements in patient's blood in pursuit of enhancing RAT performance in detecting patients. The machine learning approach employed here enabled us to test this hypothesis. The best-obtained and validated model (formed of RAT plus HB and urea) gave a predictive accuracy of 59.3% and other models with more features, that are COVID-19 related, gave even lower accuracy than this one. This analysis scheme suggests that using laboratory parameters might not afford the desired improvement in the diagnostic performance of the RAT studied here, and possibly other RAT. Another point to consider for clinicians is the parameters that should be taken into consideration when performing the test given the differences in the results between RT-qPCR and RAT. The vast difference between determinants of both assays (as shown by the random forest classification model) suggests that the differences between the results of both assays have reflected on the parameters to be considered as determinants for the assay.

We acknowledge that this analysis is limited by some factors that should be taken into account in future studies: the small sample size and the unavailability of some participant's data were due to logistic hurdles during the pandemic time. Obviously, additional samples are required for evaluating RAT. The accelerated pressure for obtaining results precluded us from evaluating the influence of sample processing procedures on the RAT accuracy, such an important factor that might alter test results. We do believe that the strength of this study lies in its performance in real-life settings. We were able to link viral load, sampling time, clinical symptoms, and laboratory parameters to the assay results and to test, by a machine learning approach, the effect of measuring blood parameters on enhancing RAT performance.

Based on the real-world data described here, Standard ™ Q COVID-19 Ag has the disadvantage of low diagnostic performance relative to the RT-qPCR; its sensitivity varies with sampling time and with the amount of viral nucleic acid contained in the sample. This test is best used for subjects with high viral load and when done early after COVID-19 symptom onset. Pending its application on large scale, our data recommend against using this test alone for COVID-19 diagnosis. RAT, therefore, has no benefit in replacing or reducing the use of RT-qPCR assay for COVID-19 diagnosis at the time of the pandemic.

Participants have agreed to publish their data anonymously in this work (19) 0.44 ** The percentages were calculated by dividing the number of subjects showing particular symptom/number of symptomatic subjects * The percentages were calculated by dividing the number of symptomatic, asymptomatic, and not reported subjects by the total number of enrolled subjects ∞ P-value refers to the significance of the difference between the results of RAT in the respective subgroups. + SD: standard deviation 

Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus

Coronavirus Diseases

Looming threat of COVID-19 infection in Africa: act collectively, and fast

Short-and potential long-term adverse health outcomes of COVID-19: a rapid review

Laboratory Diagnosis of COVID-19: Current Issues and Challenges

Comparison of four commercial RT-PCR diagnostic kits for COVID-19 in China

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

Scaling up COVID-19 rapid antigen tests: promises and challenges. The Lancet Infectious Diseases

Novel Coronavirus disease 2019 (COVID-19): new challenges and new responsibilities in developing countries

Fast, portable tests come online to curb coronavirus pandemic

COVID-19 rapid diagnostic test could contain transmission in low-and middle-income countries

Containing COVID-19 in the Emergency Department: The Role of Improved Case Detection and Segregation of Suspect Cases. Academic emergency medicine : official journal of the Society for

Evaluation of a Rapid Diagnostic Assay for Detection of SARS

Antigen in Nasopharyngeal Swabs

Field Evaluation of the Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal Samples

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Potential Use of Antigen-Based Rapid Test for SARS-CoV-2 in Respiratory Specimens in Low-Resource Settings in Egypt for Symptomatic Patients and High-Risk Contacts

Open Source Epidemiologic Statistics for Public Health

WHO COVID-19: Case Definitions: Updated in Public health surveillance for COVID-19

CDC (2020) Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19

Method agreement analysis: A review of correct methodology

Interval Estimation for a Binomial Proportion

Reprogramming of Small Noncoding RNA Populations in Peripheral Blood Reveals Host Biomarkers for Latent and Active Mycobacterium tuberculosis Infection

pcaMethods--a bioconductor package providing PCA methods for incomplete data

MetaboAnalystR 3.0: Toward an Optimized Workflow for

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein

Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences

Potential Use of Antigen-Based Rapid Test for SARS-CoV-2 in Respiratory Specimens in Low-Resource Settings in Egypt for Symptomatic Patients and High-Risk Contacts

Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Virological assessment of hospitalized patients with COVID-2019

Asymptomatic carriers of COVID-19 in a confined adult community population in Quebec: A cross-sectional study

The authors thank staff members at the "Zagazig Scientific and Medical Research Center, Zagazig University" for their assistance during the laboratory work. This work did not receive any funding.

*Test performance for RT-PCR subgroups was calculated considering the negative PCR results are the ones that lack the respective group feature.